GI Oncology
Conference Coverage
mRECIST response to kinase inhibitors predicts survival in HCC
SAN FRANCISCO – Among patients with untreated HCC given first-line kinase inhibitors, those having a response based on mRECIST criteria lived...
From the Journals
HBV, HCV, HIV testing of new cancer patients advised
Many patients with newly diagnosed cancers were unaware of their infection status, and some had no known risk factors.
News
FDA approves cabozantinib for previously treated HCC
Approval was based on improvement in overall survival versus placebo in the phase 3 CELESTIAL trial.
From the Journals
Postdiagnosis statin use lowers mortality rate for patients with HCC
Statin use after a diagnosis of hepatocellular carcinoma was associated with a reduced risk of all-cause and cancer-specific mortality.
From the Journals
Metachronous advanced neoplasia linked to diminutive polyp number, not histology
Metachronous advanced neoplasia was diagnosed in similar proportions of patients with and without high-risk diminutive polyps.
From the Journals
Aspirin, omega-3 PUFA fail to reduce adenoma detection rate in high-risk patients
Both had some evidence of chemoprotective activity in this randomized trial, despite the negative primary endpoint.
From the Journals
AGA Clinical Practice Update: Endoscopic submucosal dissection
Uptake and training in the United States have been slow, although the technique is recommended as safe and cost effective.
From the Journals
Negative colonoscopy linked with lower risk for more than 10 years
Individuals at average risk of colorectal cancer who have a negative colonoscopy show significantly lower rates of cancer for more than 10 years,...
From the Journals
Study eyed endoscopic submucosal dissection for early-stage esophageal cancer
Compared with esophagectomy, ESD was associated with significantly fewer severe adverse perioperative events and a similar rate of all-cause...
From the Journals
Staying up to date on screening may cut risk of death from CRC
Staying up to date on screening was associated with a 62% decrease in the odds of dying from colorectal cancer.